UAB
Birmingham, Alabama, 35249, United States
Location status: Recruiting
Location contact
April Riddle
CONTACT
Jonathan McConathy, MD, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT05656105
This clinical imaging study will use the small molecule translocator protein (TSPO) ligand, Fluorodeoxyglucose(18F)-labeled DPA-714, to visualize and quantify neuroinflammation in individuals with post-acute sequelae of SARS-CoV-2 (PASC) . The brain uptake of DPA-714 will be contrasted with healthy subjects.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Early Phase 1
Birmingham, Alabama, 35249, United States
Location status: Recruiting
April Riddle
CONTACT
Jonathan McConathy, MD, PhD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
11Currently enrolled in a clinical trial utilizing experimental therapies. 12. Currently taking experimental therapies 13. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.
The following exclusionary criteria apply only to PASC patients and healthy controls:
DPA-714 PET/MRI
Time frame: Injection/scan date to clinical follow-up. (Usually within 6 weeks)
PET measures of TSPO binding in brain regions including cerebral cortex, thalami, and brainstem will be quantified in symptomatic study participants and healthy volunteers will be collected and compared between groups
Contact information is provided by the study sponsor or research team.
University of Alabama at Birmingham
Other
PET Imaging of Neuroinflammation in Patients With Neurological Dysfunction After SARS-CoV-2 Infection
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06792214
COVID-19, Chronic Disease
Kingston, Ontario, Canada
View Trial Details